PubMed · 2006 · 15 citations · 0 references
MedicineNeurologyPediatricsImmunotherapyNeuroimmunologyPediatric NeurologyDemyelinating DiseasesDemyelinating DisordersInterferon-based TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyPediatric NeuroimmunologyInterferon Alfa TherapyMultiple Sclerosis TherapyPediatric Multiple Sclerosis TreatmentTherapy Tolerability
The use of beta-interferons for immunomodulating treatment of multiple sclerosis (MS) in children is rstudied. We present results of the prospective study of 22 children, aged 13-17 years, with MS treated with beta-interferon-1b (betaferon) during 2-15 (mean 10,72) months. High efficacy and good tolerability of beta-interferon-1b is demonstrated.